Home Featured

Featured

Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket

New Study: LSD Makes Brain Rhythms Faster and Increases Neural Complexity

Timothy Leary Did Not Cause the Drug War

Before the Approvals Arrive: Norway, Germany, Switzerland, the UK and Estonia at TAIP Conference 2026

From Ecstasy Rising to Peaking: Jordan Kronick on 20 Years Covering Psychedelics

What Psychedelics Have Taught Me About Paying Attention as a Father

Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In...

Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try...

Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks...

Weekly Psychedelic Policy Briefing: October 12, 2026

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks...

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic...

12 3...328 Page 1 of 328

EDITOR PICKS

Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket

New Study: LSD Makes Brain Rhythms Faster and Increases Neural Complexity

Timothy Leary Did Not Cause the Drug War

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket

New Study: LSD Makes Brain Rhythms Faster and Increases Neural Complexity

Timothy Leary Did Not Cause the Drug War

Before the Approvals Arrive: Norway, Germany, Switzerland, the UK and Estonia at TAIP Conference 2026

From Ecstasy Rising to Peaking: Jordan Kronick on 20 Years Covering Psychedelics

What Psychedelics Have Taught Me About Paying Attention as a Father

Vital Community Webinar

Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In...

Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try...

Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks...

Weekly Psychedelic Policy Briefing: October 12, 2026

How to Change Your Behavior

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks...

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic...

EDITOR PICKS

Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket

New Study: LSD Makes Brain Rhythms Faster and Increases Neural Complexity

Timothy Leary Did Not Cause the Drug War

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY